Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry


Bodur H., Yurdakul F. G., ATAMAN Ş., Cay H. F., GÜRER G., ÇAPKIN E., ...Daha Fazla

CLINICAL RHEUMATOLOGY, cilt.41, sa.7, ss.2053-2063, 2022 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 41 Sayı: 7
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1007/s10067-022-06145-8
  • Dergi Adı: CLINICAL RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.2053-2063
  • Anahtar Kelimeler: Disease modifying anti rheumatic drugs, Drug switching, Remission induction, Spondyloarthritis, ANKYLOSING-SPONDYLITIS, DISEASE-ACTIVITY, INHIBITORS, THERAPY, HLA-B27
  • Atatürk Üniversitesi Adresli: Evet

Özet

Objectives Factors associated with disease activity of axial spondyloarthritis (axSpA) and switching of biologic disease-modifying anti-rheumatic drugs have not been clearly defined. We aimed to evaluate clinical characteristics of patients with axSpA, factors related to remission in treat to target era and predictive factors for biologic disease-modifying anti-rheumatic drug switching.